Featured News

Zhang and McGill offer an in-depth analysis on clinical guidelines for chronic kidney disease in type 2 diabetes 

In March, Rong Mei Zhang, MD; Janet B. McGill, MD, and colleagues had their journal article titled “Clinical implications and guidelines for CKD in type 2 diabetes,” published in Volume 38, Issue 3 of Nephrology Dialysis Transplantation

Kidney disease is a complication of type 2 diabetes (T2D) and carries a high morbidity and mortality rate. Its prevalence is rising due to increasing numbers of individuals with T2D. Results of many clinical trials “testing novel therapies to reduce the progression of chronic kidney disease (CKD), cardiovascular morbidity, in particular hospitalization for heart failure, and mortality,” have been used to inform guidelines for CKD management in T2D. 

In analysis of these existing guidelines, the authors state that screening for CKD is recommended, including management of blood pressure with RAS inhibition and achieving excellent glucose control. They also note recent additions to guidelines that aim to improve CKD outcomes in T2D, which are sodium-glucose cotransporter-2 (SGLT2) inhibition and finerenone, a mineralocorticoid receptor blocker. 

Rong M Zhang and others, Clinical implications and guidelines for CKD in type 2 diabetes, Nephrology Dialysis Transplantation, Volume 38, Issue 3, March 2023, Pages 542–550, https://doi.org/10.1093/ndt/gfac285